AM-111 in the Treatment of Acute Inner Ear Hearing Loss : Efficacy and Safety of AM-111 in the Treatment of Acute Inner Ear Hearing Loss
This phase III study is assessing the drug's safety and is aiming to demonstrate efficacy of intratympanic AM-111 injections in the treatment of severe to profound idiopathic sudden sensorineural hearing loss (ISSNHL). The active pharmaceutical ingredient of AM-111 is the JNK inhibitor (D-JNKI-1), a synthetic peptide consisting of 31 D-amino acids, which acts as a c-Jun N-terminal kinase (JNK) ligand..
| Medienart: |
|
|---|
Klinische Studie| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
ClinicalTrials.gov - (2023) vom: 14. Sept. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
610 |
|---|
| Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: September 25, 2015, Last downloaded: ClinicalTrials.gov processed this data on September 20, 2023, Last updated: September 20, 2023 |
|---|
| Study ID: |
NCT02561091 |
|---|---|
| Veröffentlichungen zur Studie: |
|
| fisyears: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
CTG001989596 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | CTG001989596 | ||
| 003 | DE-627 | ||
| 005 | 20230920010916.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210408s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)CTG001989596 | ||
| 035 | |a (UBBS_Klinische_Studien)NCT02561091 | ||
| 035 | |a (UBBS_Klinische_Studien)AM-111-CL-13-01 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a AM-111 in the Treatment of Acute Inner Ear Hearing Loss |b Efficacy and Safety of AM-111 in the Treatment of Acute Inner Ear Hearing Loss |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: September 25, 2015, Last downloaded: ClinicalTrials.gov processed this data on September 20, 2023, Last updated: September 20, 2023 | ||
| 520 | |a This phase III study is assessing the drug's safety and is aiming to demonstrate efficacy of intratympanic AM-111 injections in the treatment of severe to profound idiopathic sudden sensorineural hearing loss (ISSNHL). The active pharmaceutical ingredient of AM-111 is the JNK inhibitor (D-JNKI-1), a synthetic peptide consisting of 31 D-amino acids, which acts as a c-Jun N-terminal kinase (JNK) ligand. | ||
| 650 | 2 | |a Hearing Loss | |
| 650 | 2 | |a Deafness | |
| 650 | 2 | |a Hearing Loss, Sensorineural | |
| 650 | 4 | |a Study Type: Interventional | |
| 650 | 4 | |a Recruitment Status: Completed | |
| 650 | 4 | |a Phase: Phase 3 | |
| 650 | 4 | |a 610 | |
| 773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2023) vom: 14. Sept. |
| 773 | 1 | 8 | |g year:2023 |g day:14 |g month:09 |
| 856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT02561091 |z kostenfrei |3 Volltext |
| 912 | |a GBV_CTG | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 14 |c 09 | ||